HuidaGene Therapeutics

Executive Summary

HuidaGene Therapeutics is a preclinical-stage Chinese gene-editing company founded in 2019, focused on developing CRISPR-based therapies for monogenic disorders. With a pipeline of in vivo and ex vivo programs targeting high-unmet-need diseases in ophthalmology, metabolism, and other genetic areas, the company aims to become a leader in precision genetic medicine. Despite being in early stages, HuidaGene's proprietary gene-editing platforms and strategic location in Shanghai position it to address significant patient populations in Asia and globally. The company's progress will depend on advancing its lead candidates toward clinical trials and securing partnerships or financing to support development.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead gene-editing candidate in hereditary eye disease65% success
• Q3 2026Preclinical proof-of-concept data for metabolic disorder program70% success
• Q4 2026Series B financing or strategic partnership announcement60% success